AICAR
AICAR is a nucleoside analog studied for AMPK activation, exercise-mimetic signaling, endurance support, and metabolic adaptation.
Overview
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), a major regulator of cellular energy balance. It is not FDA-approved for therapeutic use and is prohibited in sports by WADA as a metabolic modulator.
Preclinical models describe increased endurance, fatty-acid oxidation, glucose uptake, and mitochondrial biogenesis, while human safety discussion largely comes from intravenous acadesine literature rather than modern subcutaneous peptide protocols.
At a Glance
Protocol
Suggested daily titration approach starting conservatively and increasing every two weeks.
Inject once daily subcutaneously using the 3.0 mL dilution to keep measurements readable. The conservative table below reflects the lower-dose research approach; the source also mentions advanced escalation up to 5 mg daily. Human efficacy remains unconfirmed despite strong preclinical endurance data.
Dose progression
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
How AICAR works.
AICAR is metabolized intracellularly to ZMP, an AMP analog that activates AMPK. This drives glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis, creating the well-known exercise-mimetic research profile.
Landmark animal studies reported major endurance improvements in sedentary mice, but human evidence is far less mature. Human safety discussion often references intravenous acadesine literature rather than direct subcutaneous AICAR protocols.
Effects
Observations from clinical or preclinical literature.
Caution
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
CoFactors
Life Factors
Complementary strategies for best outcomes.
Metrics
Day-to-day metrics worth tracking through the protocol.
- Exercise endurance and recovery - track duration, work output, and recovery time
- Body composition - monitor weight and fat-loss trends
- Fasting glucose - useful given the metabolic focus of AMPK activation
- Injection-site reactions - note redness, swelling, or discomfort
Labs
Baseline and periodic bloodwork to monitor systemic health during the protocol.
Supplies Calculator
Estimates assume the schedule defined for this peptide.
Dose Calculator
Dose Calculator
Preparation
Careful technique preserves potency. Solution should be clear — do not shake.
- Allow vial to reach room temperature for 15–20 minutes before reconstitution.
- Draw the chosen bacteriostatic water volume with a sterile syringe.
- Inject slowly down vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 30 days; discard any unused solution after 30 days.
Technique
General subcutaneous guidance from clinical best-practice resources.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Storage
Notes
Notes
References
- Cell (2008)Narkar et al., exercise-mimetic effects of AMPK and PPARdelta agonism.https://pubmed.ncbi.nlm.nih.gov/18674809/
- CDCSubcutaneous injection route guidance.https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
- WHO (NCBI Bookshelf)Injection-safety guidance for subcutaneous administration.https://www.ncbi.nlm.nih.gov/books/NBK390474/